
Daniel Crean

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5208015/publications.pdf Version: 2024-02-01



DANIEL CREAN

#	Article	IF	CITATIONS
1	Targeting NR4A Nuclear Receptors to Control Stromal Cell Inflammation, Metabolism, Angiogenesis, and Tumorigenesis. Frontiers in Cell and Developmental Biology, 2021, 9, 589770.	3.7	36
2	Protein kinase D, ubiquitin and proteasome pathways are involved in adenosine receptor-stimulated NR4A expression in myeloid cells. Biochemical and Biophysical Research Communications, 2021, 555, 19-25.	2.1	2
3	The NR4A agonist, Cytosporone B, attenuates pro-inflammatory mediators in human colorectal cancer tissue exÂvivo. Biochemical and Biophysical Research Communications, 2021, 554, 179-185.	2.1	8
4	HIF hydroxylase inhibitors decrease cellular oxygen consumption depending on their selectivity. FASEB Journal, 2020, 34, 2344-2358.	0.5	26
5	Hydroxylase Inhibition Selectively Induces Cell Death in Monocytes. Journal of Immunology, 2019, 202, 1521-1530.	0.8	7
6	Subcellular Localization of NR4A2 Orphan Nuclear Receptor Expression in Human and Mouse Synovial Joint Tissue. Methods in Molecular Biology, 2019, 1966, 17-26.	0.9	4
7	Lipoxins Protect Against Inflammation in Diabetes-Associated Atherosclerosis. Diabetes, 2018, 67, 2657-2667.	0.6	60
8	Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation. Drug Delivery and Translational Research, 2018, 8, 1421-1435.	5.8	12
9	Hypoxia and inflammatory bowel disease. Microbes and Infection, 2017, 19, 210-221.	1.9	53
10	NR4A Receptors Differentially Regulate NF-κB Signaling in Myeloid Cells. Frontiers in Immunology, 2017, 8, 7.	4.8	33
11	Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis. Cardiovascular Diabetology, 2017, 16, 143.	6.8	48
12	M1- and M2-Type Macrophage Responses Are Predictive of Adverse Outcomes in Human Atherosclerosis. Frontiers in Immunology, 2016, 7, 275.	4.8	123
13	The role of HIF in immunity and inflammation. Molecular Aspects of Medicine, 2016, 47-48, 24-34.	6.4	115
14	Molecular Interactions between NR4A Orphan Nuclear Receptors and NF-κB Are Required for Appropriate Inflammatory Responses and Immune Cell Homeostasis. Biomolecules, 2015, 5, 1302-1318.	4.0	66
15	Development of an in vitro renal epithelial disease state model for xenobiotic toxicity testing. Toxicology in Vitro, 2015, 30, 128-137.	2.4	36
16	Adenosine Modulates NR4A Orphan Nuclear Receptors To Attenuate Hyperinflammatory Responses in Monocytic Cells. Journal of Immunology, 2015, 195, 1436-1448.	0.8	43
17	Specialised lipid mediators and their targets. Seminars in Immunology, 2015, 27, 169-176.	5.6	20
18	Interleukin-19 as a translational indicator of renal injury. Archives of Toxicology, 2015, 89, 101-106.	4.2	23

DANIEL CREAN

#	Article	IF	CITATIONS
19	Modulation of expression in BEAS-2B airway epithelial cells of α-l-fucosidase A1 and A2 by Th1 and Th2 cytokines, and overexpression of α-l-fucosidase 2. Molecular and Cellular Biochemistry, 2014, 390, 101-113.	3.1	10
20	Tumor Necrosis Factor Inhibition Modulates Thrombospondin-1 Expression in Human Inflammatory Joint Disease through Altered NR4A2 Activity. American Journal of Pathology, 2013, 183, 1243-1257.	3.8	29
21	Inhibition of protein translation as a mechanism of acidotic pH protection against ischaemic injury through inhibition of CREB mediated tRNA synthetase expression. Experimental Cell Research, 2013, 319, 3116-3127.	2.6	7
22	Histamine contributes to increased RANKL to osteoprotegerin ratio through altered nuclear receptor 4A activity in human chondrocytes. Arthritis and Rheumatism, 2012, 64, 3290-3301.	6.7	17
23	Glucose reintroduction triggers the activation of Nrf2 during experimental ischemia reperfusion. Molecular and Cellular Biochemistry, 2012, 366, 231-238.	3.1	23
24	Identification and dissection of the Nrf2 mediated oxidative stress pathway in human renal proximal tubule toxicity. Toxicology in Vitro, 2011, 25, 613-622.	2.4	75